Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674748 | 0.80 | SMN1; SMN2 (0.33) | GPR55SMN1; SMN2 | |
| SCHEMBL20446843 | 0.80 | SMN1; SMN2 (0.33) | GPR55SMN1; SMN2 | |
| SCHEMBL2806741 | 0.75 | — | — | |
| SCHEMBL6129249 | 0.72 | L3MBTL1 (0.32) | L3MBTL1GAAALDH1A1POLBMAPT | |
| SCHEMBL8461903 | 0.72 | ACHE (0.35) | ACHE | |
| SCHEMBL10446742 | 0.66 | APAF1 (0.39) | L3MBTL1GAAGPR55ALDH1A1POLB | |
| SCHEMBL3458804 | 0.65 | SMN1; SMN2 (0.39) | GPR55ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL9644150 | 0.65 | ALDH1A1 (0.32) | L3MBTL1GAAALDH1A1POLBMAPT | |
| SCHEMBL120459 | 0.64 | SMN1; SMN2 (0.40) | L3MBTL1GAAGPR55ALDH1A1POLB | |
| SCHEMBL469461 | 0.63 | L3MBTL1 (0.37) | L3MBTL1GAAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050000529-A1 | Method and compositions for imparting cooling effect to tobacco products | VECTOR TOBACCO INC. | 2005-01-06 | — | — | US | claimed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | claimed |
| US-6592884-B2 | Food, cosmetics, drugs; cooling skin, mouth | NESTEC S.A. (CH) | 2003-07-15 | — | — | US | claimed |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | NESTEC S.A. (CH) | 2002-02-21 | — | — | US | claimed |
| US-20050000529-A1 | Method and compositions for imparting cooling effect to tobacco products | VECTOR TOBACCO INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1455609-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | Vector Tobacco Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6592884-B2 | Food, cosmetics, drugs; cooling skin, mouth | NESTEC S.A. (CH) | 2003-07-15 | — | — | US | disclosed |
| WO-2003053176-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | VECTOR TOBACCO INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | NESTEC S.A. (CH) | 2002-02-21 | — | — | US | disclosed |
| EP-1157617-A2 | Use of alpha-keto enamine derivatives as ingredients | Société des Produits Nestlé S.A. (CH) | 2001-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | PKN2, OPRD1, PKN1 | L3MBTL1 3770/4885GAA 3674/4885GPR55 946/4885 |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | ECH1, KMO, PKN1 | L3MBTL1 3305/4885GAA 3280/4885GPR55 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.